Crossmark

Do We Need AI to Diagnose AI? Diagnosis and Management of Adrenal Insufficiency Following Steroid Therapy in a Patient with Inflammatory Bowel Disease

Crossref DOI link: https://doi.org/10.1007/s10620-023-08123-9

Published Online: 2023-10-13

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Law, Cindy C. Y.

Peraza, Jellyana

Viera Feliciano, Natalia

Ungaro, Ryan C. https://orcid.org/0000-0001-8687-3758
Cheesman, Khadeen

Colombel, Jean-Frédéric

Livanos, Alexandra E.
License Information

Text and Data Mining valid from 2023-10-13

Version of Record valid from 2023-10-13
More Information

Article History

Received: 21 August 2023

Accepted: 19 September 2023

First Online: 13 October 2023

Declarations

:

: Ryan Ungaro has served as a consultant, advisory board member, or received speaker’s fees from AbbVie, Bristol Myers Squibb, Celltrion, Janssen, Lilly, Pfizer, Roivant, and Takeda. Dr. Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals, Takeda and Bristol Myers Squibb; receiving payment for lectures from AbbVie, and Takeda; receiving consulting fees from AbbVie, Amgen, AnaptysBio, Allergan, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Genentech (Roche), Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Invea, Iterative Scopes, Merck, Landos, Microba Life Science, Novartis, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Prometheus, Sanofi, Seres, Takeda, Teva, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development. The remaining authors declare that they have no confict of interest to disclose.

: The participant has provided verbal consent to the submission of the case report to the journal.

Document is current

Any future updates will be listed below